Spark Therapeutics News

Spark Therapeutics, a Philadelphia-based developer of one-time gene therapy products, has raised $72.8 million in Series B funding. Sofinnova Ventures led the round, and was joined by Brookside, Deerfield, Rock Springs Capital, T. Rowe Price, Wellington and “two undisclosed dedicated healthcare funds.” Return backer The Children’s Hospital of Philadelphia also participated.

©2020 PACT All Rights Reserved